Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 1/20 | 0.38 |
| ▸ | NAPEPLD | Q6IQ20 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | CACNA1G | O43497 | 3/20 | 0.36 |
| ▸ | CACNA1H | O95180 | 3/20 | 0.36 |
| ▸ | CACNA1I | Q9P0X4 | 3/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | VCP | P55072 | 6/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | PPM1D | O15297 | 1/20 | 0.34 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2815946 | 0.87 | MC4R (0.44) | CACNA1GCACNA1HCACNA1I | |
| SCHEMBL2811933 | 0.86 | CACNA1G (0.41) | CACNA1GCACNA1HCACNA1I | |
| SCHEMBL2814288 | 0.86 | KMT2A (0.39) | CACNA1GCACNA1HCACNA1IRAB9A | |
| SCHEMBL538581 | 0.85 | CACNA1G (0.39) | CACNA1GCACNA1HCACNA1I | |
| SCHEMBL2812037 | 0.84 | KCNH2 (0.39) | CACNA1GCACNA1HCACNA1I | |
| SCHEMBL2812136 | 0.84 | POLB (0.41) | CACNA1GCACNA1HCACNA1I | |
| SCHEMBL2811169 | 0.84 | HPGD (0.38) | NPSR1CACNA1GCACNA1HCACNA1I | |
| SCHEMBL2813056 | 0.84 | KMT2A (0.37) | CACNA1GCACNA1HCACNA1INPC1RAB9A | |
| SCHEMBL2812146 | 0.82 | ALDH1A1 (0.40) | CACNA1GCACNA1HCACNA1I | |
| SCHEMBL537588 | 0.82 | ALDH1A1 (0.45) | NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2414359-A1 | PERI-FUSED PYRAZOLO-PYRIMIDINE COMPOUNDS | ArQule, Inc. (US) | 2012-02-08 | — | — | EP | claimed |
| WO-2010114905-A1 | PERI-FUSED PYRAZOLO-PYRIMIDINE COMPOUNDS | ARQULE, INC. (US) | 2010-10-07 | — | — | WO | claimed |
| US-8343983-B2 | Substituted pyrazolo-pyrimidine compounds | ARQULE, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-20100249110-A1 | SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS | ARQULE, INC. (US) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249110-A1 | SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS | DPYD, TYMP, TP53 | ENPP2 2545/4885NAPEPLD 1799/4885NPSR1 3656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.